


CLAIM AMENDMENTS

~~1-18~~ 1-17. (canceled).

~~18~~ 19. (New) A compound having the structure



or pharmaceutically acceptable salts thereof, prodrug esters thereof, or all stereoisomers thereof, wherein

A, B and D are each -CH or N;

$$\begin{array}{c} R^3 \\ | \\ -(C)- \\ | \\ R^4 \end{array}$$

X¹ is $\begin{array}{c} R^3 \\ | \\ -(C)- \\ | \\ R^4 \end{array}$, where n is 1, 2 or 3, and where R³ and R⁴ are independently H, alkyl, arylalkyl or cycloalkyl, or R³ and R⁴ can be taken together with the carbon to which they are attached to form a 5 to 8 carbon containing ring; and R⁵ is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl;

R is H, alkyl, alkenyl, aryl, arylalkyl, heterocycloalkyl, cycloalkyl, or cycloalkylalkyl;

R¹ is alkyl, arylalkyl, aryl, alkenyl, heterocyclo, heterocycloalkyl, $\begin{array}{c} \text{---N---heterocycle} \\ | \\ R^{5a} \end{array}$

(where R^{5a} can be any of the R⁵ groups), cycloalkyl, cycloalkylalkyl or $\begin{array}{c} R^6 \\ | \\ \text{---N---}R^7 \end{array}$ (where R⁶ and R⁷ are independently selected from H, aryl, alkyl, arylalkyl or cycloalkyl, or R⁶ and R⁷ can be taken together with the nitrogen atom to which they are attached to form a 5 to 8 membered ring); or R and R¹ can be taken together with the -N-S- atoms to form a 5- to 8-membered ring;


X² is a single bond, $\begin{array}{c} \text{---N---} \\ | \\ R^8 \end{array}$ or -O- (where R⁸ is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl);

R^2 is H, alkyl, arylalkyl, $-\overset{\text{O}}{\parallel}{\text{C}}-\text{alkyl}$, $-\overset{\text{O}}{\parallel}{\text{C}}-\text{arylalkyl}$, $-\text{CH}_2\overset{\text{O}}{\parallel}{\text{C}}-\text{O}-R^{10}$ or
 $-\text{CH}_2\overset{\text{O}}{\parallel}{\text{C}}-\text{N}(\text{R}^{10})\text{R}^{11}$ (where R^{10} and R^{11} are independently selected from H, alkyl, arylalkyl or
 cycloalkyl, or R^{10} and R^{11} can be taken together with the nitrogen to which they are
 attached to form a 5- to 8-membered ring); and

Q is $\text{R}^{12}-\overset{\text{H}}{\underset{\text{NC}-\text{N}}{\parallel}}{\text{C}}-\text{N}-$, (where R^{12} is alkyl, arylalkyl, aryl, $-\text{N}(\text{R}^{15})\text{R}^{16}$, heterocycle,
 heterocycloalkyl, where R^{15} and R^{16} are independently selected from H, alkyl, arylalkyl,
 aryl, heterocyclo, cycloalkyl, amino, aminoalkyl, or heterocycloalkyl, or R^{15} and R^{16} can
 be taken together with the nitrogen to which they are attached to form a 5- to 8-
 membered ring which may optionally contain an additional nitrogen atom in the ring
 and/or an amino group or an aminoalkyl group attached to the ring).


19

20. (New) The compound as defined in Claim 18 having the structure




20

21. (New) The compound as defined in Claim 18 having the structure



21

22. (New) The compound as defined in Claim 18 having the structure




22

23. (New) The compound as defined in Claim 18 wherein

R is H;
R¹ is aryl or alkyl;
X² is O or a single bond; and
R² is H.

²³
~~24.~~ (New) A compound of claim ¹⁸~~19~~:



²⁴
~~25.~~ (New) A pharmaceutical composition comprising a compound as defined in Claim ¹⁸~~19~~ in combination with one or more components selected from the group consisting of cyclooxygenase inhibitors, fibrinogen antagonists, diuretics, angiotensin converting enzyme inhibitors, angiotensin II antagonists, thrombolytic agents, calcium channel blocking agents, thromboxane receptor antagonists, prostacyclin mimetics and phosphodiesterase inhibitors.